Alan Copa, Pharm.D. Joins Novum Pharmaceutical Research Services as Vice President to Lead Clinical Expansion
PITTSBURGH, Aug. 5, 2013 /PRNewswire/ -- Dr. Alan Copa has joined the leadership team of Novum Pharmaceutical Research Services as Vice President, the company announced today. "Dr. Copa brings a high degree of experience, knowledge, and innovation to Novum," said Christopher H. Chamberlain, Novum's Chief Executive Officer. "He will help Novum expand clinic capacity and capabilities to meet our clients' timelines and needs while championing Novum's commitment to subject safety and study integrity," Chamberlain added.
Novum's clinical footprint currently includes locations in Pittsburgh, PA, Houston, TX, and Las Vegas, NV. The company will release further details on expansion plans and services later in 2013.
Prior to joining Novum, Dr. Copa was the Chief Scientific Officer of PRACS Institute. In his 20-year tenure at the company, Copa served in numerous clinical and operational lead roles, and was principal investigator presiding over 1000 projects spanning early phase, dermatology, pharmacokinetic and other study disciplines.
Dr. Copa received a Doctor of Pharmacy degree from the College of Pharmacy, University of Minnesota. He then completed a two year fellowship in Cardiovascular Research and Critical Care Medicine at the University of Minnesota. He is a member of the American Association of Pharmaceutical Scientists and the American Society of Clinical Pharmacology and Therapeutics.
About Novum PRS
Novum is a leading contract research organization ("CRO") that provides Phase I through IV clinical research, data management, statistical and reporting services to the pharmaceutical and related industries. Founded in 1972, it operates Phase I research facilities with a current total of 550 beds in three USA locations. Novum's clinical trials management group currently focuses on performing Phase II through IV clinical endpoint studies requiring large patient numbers. Please visit www.novumprs.com for more information.
SOURCE Novum Pharmaceutical Research Services